http://www.neuronbio.com/Noticias de Neuron BIOhttp://neuronbio.com/Noticias.aspx?id=389Tue, 04 Sep 2012 23:00:00 GMTNeuron BioPharma, the pharmaceutical division of Neuron Bio, has recently published a paper in the specialist journal Brain Research Bulletin presenting the results of its research with zebrafish (Danio rerio) into the benefits to the nervous system resulting from the consumption of a diet rich in DHA. The paper, entitled “Administration of docosahexaenoic acid before birth and until aging decreases kainate-induced seizures in adult zebrafish”, demonstrates how the consumption of DHA from before birth until old age has beneficial effects on the brain, affording protection against the continuous, accumulative aggression to which it is subject throughout life. To undertake the research the zebrafish model was used, an animal model for which Neuron Bio is renowned and has wide experience in using to study diseases of the nervous system. This work represents a continuation of the general research developed by Neuron’s biopharmaceutical division into the modulation of lipids in the brain as a possible therapeutic target in the fight against Alzheimer’s disease. ]]>http://neuronbio.com/Noticias.aspx?id=390Wed, 02 May 2012 23:00:00 GMTNeuron BioPharma, whose research is centred on understanding the implications of cholesterol regulation in the brain, has just published a paper in the American Journal of Alzheimer’s Disease & Other Dementias in which it puts forward ideas as to how best clinical assays with statins should be conducted in order to observe their neuron protector effects. For the past ten years a considerable number of studies have suggested a relationship between cholesterol regulation and Alzheimer’s disease, whilst epidemiological studies have shown a relationship between treatment with statins and a decrease in the risk of suffering Alzheimer’s disease. Thus, a large number of assays have been undertaken to determine whether statins are able to prevent the progress of the disease. Until now, however, these studies have not provided any clear evidence for the efficacy of statins. The study entitled, ‘How Statins Could Be Evaluated Successfully in Clinical Trials for Alzheimer’s Disease’ was written jointly by researchers at Neuron BioPharma, the Paris - Sud University and the Gui de Chauliac Hospital in Montpellier with the aim of discovering why studies with statins have not worked so far in patients with Alzheimer’s disease. The paper concludes that among the possible reasons may be the incorrect choice of statins, a lack of biomarkers necessary to test the efficacy of the statins and even the time when therapy is begun. It is hoped that the explanations for the failures in clinical assays given in this publication might serve as a guideline for the choice of new statins and for the development of new clinical assays with the aim of proving the therapeutic efficacy of new statins such as NST0037, developed by Neuron BioPharma to combat Alzheimer’s disease.]]>http://neuronbio.com/Noticias.aspx?id=385Fri, 27 Apr 2012 23:00:00 GMTNeuron BioPharma division of Neuron Bio, Javier S. Burgos, gave a talk in Salamanca on 25 April during a seminar at the Instituto de Neurociencias de Castilla y León (The Institute of Neurosciences of Castilla and Leon), in which he described the advances in research made by this pharmaceuticals division of the company, focusing particularly on its research into the compound NST 0037, which shows neuroprotective capacity. Dr Burgos gave a speech entitled, “Developing a new statin to prevent Alzheimer’s disease”, in which he explained Neuron BioPharma’s line of research, which has demonstrated that statins (drugs that reduce cholesterol levels) are able to prevent the neurodegeneration associated with Alzheimer’s disease. As a result of its research so far, Neuron BioPharma has developed and patented a new statin that decreases cholesterol levels in the blood, prevents neuron death and protects against loss of memory. The seminar was organised by the International Campus of Excellence of the University of Salamanca to strengthen the relationship between universities and companies in the field of biotechnology.]]>